Tolvaptan-Octreotide LAR Combination in ADPKD

NCT03541447 | Completed Phase 2 DMC

• 2 other identifiers: TOOL2017-004701-40
• Study Type: interventional
• Target: 20
• Locations: 1 country
• Sites: 1

Brief Summary

Autosomal Dominant Polycystic Kidney Disease (ADPKD) is a leading cause of End Stage Kidney Disease (ESKD) worldwide. Elevated levels of 3', 5' - cyclic AMP (cAMP) play a central role in the pathogenesis and progression of the disease. Vasopressin antagonists and somatostatin analogues, which indirectly reduce adenyl cyclase 6 activity, have been found to markedly reduce renal tubular cell proliferation and cyst growth in experimental models of ADPKD. In combination, the two treatments show a clear additive effect and may significantly reduce renal cystic and fibrotic volume as well as cAMP levels to wild type levels. The vasopressin antagonist Tolvaptan and the somatostatin analogue Octreotide share a similar renoprotective effect also in human disease. Both medications effectively slow total kidney and cystic volume (TKV and TCV, respectively) growth and glomerular filtration rate (GFR) decline in patients with ADPKD. The short-term effect of both medications appear to be larger when the GFR is normal or even higher than normal and kidney volumes are still relatively stable. On the basis of experimental data, it is conceivable that Tolvaptan and Octreotide LAR should have an additive effect also in human disease, during initial treatment as well as in the long-term. To address the working hypothesis of an additional short-term effect of Tolvaptan and Octreotide, we propose to run a pilot, explorative, randomized, placebo-controlled, clinical trial with a Cross-Over Design to compare the short-term effects of Tolvaptan monotherapy and Tolvaptan plus Octreotide LAR combination therapy on TKV as assessed by MRI, and on GFR as directly measured by the iohexol plasma clearance technique in ADPKD patients with normal (80 to 120 ml/min/1.73m2) kidney function or even kidney hyperfiltration (GFR ≥120 ml/min/1.73m2).

Conditions

Autosomal Dominant Polycystic Kidney Disease

Keywords

ADPKD, Tolvaptan, Octrotide LAR

Outcome Measures

Primary Outcomes (1)

• Glomerular Filtration Rate (GFR)

  GFR will be assessed by the Iohexol Plasma Clearance Technique

  Changes from 4 weeks before randomization at baseline, 1,4,8,9,12 and 16 weeks after the randomization.

Secondary Outcomes (1)

• Total Kidney Volume (TKV)

  Changes from baseline at 4,8,12 and 16 weeks after the randomization.

Study Arms (2)

Tolvaptan plus Octreotide LAR / Tolvaptan plus Placebo

EXPERIMENTAL

Patients will receive a first 4-week treatment period with Tolvaptan up to 120 mg/die, according to tolerability, and a single dose of Octreotide LAR (two 20 mg i.m. injections). Then, after a period of wash-out, each patient will cross over to the other treatment arm for a second 4-week treatment period with Tolvaptan plus a single dose of placebo (two i.m. injections of 0.9% NaCl solution)

Drug: Tolvaptan; Drug: Octreotide LAR; Other: Placebo

Tolvaptan plus placebo/Tolvaptan plus Octreotide LAR

EXPERIMENTAL

Patients will receive a first 4-week treatment period with Tolvaptan up to 120 mg/die, according to tolerability, and a single dose of placebo (two i.m. injections of 0.9% NaCl solution). Then, after a period of wash-out, each patient will cross over to the other treatment arm for a second 4-week treatment period with Tolvaptan plus a single dose of Octreotide LAR (two 20 mg i.m. injections).

Drug: Tolvaptan; Drug: Octreotide LAR; Other: Placebo

Interventions

Tolvaptan DRUG

Starting morning and afternoon doses of 45 and 15 mg, respectively, to be up titrated every two days to 60 and 30 mg and then to 90 and 30 mg, according to tolerability.

Also known as: Jinarc

Tolvaptan plus Octreotide LAR / Tolvaptan plus Placebo; Tolvaptan plus placebo/Tolvaptan plus Octreotide LAR

Octreotide LAR DRUG

A single dose of two 20 mg i.m. injections.

Also known as: Sandostatin LAR

Tolvaptan plus Octreotide LAR / Tolvaptan plus Placebo; Tolvaptan plus placebo/Tolvaptan plus Octreotide LAR

Placebo OTHER

A single dose of two 20 mg i.m. injections.

Also known as: NaCl 0.9%

Tolvaptan plus Octreotide LAR / Tolvaptan plus Placebo; Tolvaptan plus placebo/Tolvaptan plus Octreotide LAR

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Adult (\>18-yr-old) men and women, with a clinical and ultrasonographic diagnosis of ADPKD;
• Serum creatinine \< 1.0 mg/dl (for man) and \< 1.2 mg/dl (for woman) and changes in serum creatinine (and creatinine clearance when available) \<30% over the last six months;
• Creatinine clearance \> 80 ml/min/1.73m2 measured one to two weeks apart during the pre-screening period;
• GFR ≥ 80 ml/min/1.73m2 (by iohexol plasma clearance technique) at screening and baseline evaluations;
• TKV ranging between 1000 and 2000 ml at screening (by ultrasound imaging) and at baseline (by MRI) evaluations;
• Female participants must be of non-childbearing potential or must agree to abstinence or use a highly effective form of contraception;
• Written informed consent.

You may not qualify if:

• Patients with concomitant systemic, renal parenchymal or urinary tract disease;
• Diabetes;
• Overt proteinuria (urinary protein excretion rate \>1 g/24 hours);
• Abnormal urinalysis suggestive of concomitant, clinically significant glomerular disease, urinary tract lithiasis, infection or obstruction, biliary tract lithiasis or obstruction;
• Hemorrhagic or complicated cysts which might acutely affect kidney function and volumes;
• QT-related ECG abnormalities;
• Cancer and major systemic diseases that could prevent completion of the planned follow-up or interfere with data collection or interpretation;
• Hypersensitivity to the IMP active substance or to any of the excipients or to benzazepine or benzazepine derivatives;
• Concomitant treatment with drugs that may affect glomerular hemodynamics during the three months before the beginning of the study (including ACE inhibitors, angiotensin receptor blockers, aldosterone antagonists and non-steroideal anti-inflammatory medications);
• Elevated liver enzymes and/or signs or symptoms of liver injury prior to initiation of treatment that meet the requirements for permanent discontinuation of tolvaptan
• Patients with anuria, volume depletion and hypernatraemia
• Patients who cannot perceive or respond to thirst
• Ferro-magnetic prosthesis, aneurysm clips, severe claustrophobia or any other contraindication to MRI evaluation;
• Psychiatric disorders and any condition that could prevent full comprehension of the purposes and risks of the study;
• Pregnant or lactating;

Sponsors & Collaborators

• Mario Negri Institute for Pharmacological Research: lead
• Otsuka Pharmaceutical Italy S.r.l.: collaborator

Study Sites (1)

CRC per le Malattie Rare Aldo e Cele Daccò

Ranica, Bergamo, 24020, Italy

Location

Related Publications (2)

• St Pierre K, Cashmore BA, Bolignano D, Zoccali C, Ruospo M, Craig JC, Strippoli GF, Mallett AJ, Green SC, Tunnicliffe DJ. Interventions for preventing the progression of autosomal dominant polycystic kidney disease. Cochrane Database Syst Rev. 2024 Oct 2;10(10):CD010294. doi: 10.1002/14651858.CD010294.pub3.

  PMID: 39356039 DERIVED

• Trillini M, Caroli A, Perico N, Remuzzi A, Brambilla P, Villa G, Perna A, Peracchi T, Rubis N, Martinetti D, Caruso M, Leone VF, Cugini D, Carrara F, Remuzzi G, Ruggenenti P; TOOL Study Group. Effects of Octreotide-Long-Acting Release Added-on Tolvaptan in Patients with Autosomal Dominant Polycystic Kidney Disease: Pilot, Randomized, Placebo-Controlled, Cross-Over Trial. Clin J Am Soc Nephrol. 2023 Feb 1;18(2):223-233. doi: 10.2215/CJN.0000000000000049.

  PMID: 36754009 DERIVED

MeSH Terms

Conditions

Polycystic Kidney, Autosomal Dominant

Interventions

Tolvaptan; Sodium Chloride

Condition Hierarchy (Ancestors)

Polycystic Kidney Diseases; Kidney Diseases, Cystic; Kidney Diseases; Urologic Diseases; Female Urogenital Diseases; Female Urogenital Diseases and Pregnancy Complications; Urogenital Diseases; Male Urogenital Diseases; Abnormalities, Multiple; Congenital Abnormalities; Congenital, Hereditary, and Neonatal Diseases and Abnormalities; Ciliopathies; Genetic Diseases, Inborn

Intervention Hierarchy (Ancestors)

Benzazepines; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; Heterocyclic Compounds; Chlorides; Hydrochloric Acid; Chlorine Compounds; Inorganic Chemicals; Sodium Compounds

Study Officials

• Giuseppe Remuzzi, MD

  CRC per le Malattie Rare Aldo e Cele Daccò

  STUDY CHAIR

Study Design

• Study Type: interventional
• Phase: phase 2
• Allocation: RANDOMIZED
• Masking: QUADRUPLE
• Who Masked: PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
• Purpose: TREATMENT
• Intervention Model: CROSSOVER
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: May 17, 2018
• First Posted: May 30, 2018
• Study Start: December 12, 2018
• Primary Completion: December 23, 2021
• Study Completion: December 23, 2021
• Last Updated: November 3, 2022

Record last verified: 2022-11

Data Sharing

• IPD Sharing: Will not share

Locations

IT (1)